ClinicalTrials.gg
CompletedNCT02513459Updated Apr 24, 2020Results posted

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

A Phase 2 interventional study of Risankizumab 600 mg IV and Risankizumab 180 mg SC in Crohn Disease, sponsored by AbbVie. Completed at 28 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies testing risankizumab in Crohn Disease — 7 open to participants now, 10 under way, 6 of them phase 3. risankizumab · Crohn Disease.

Enrollment
13th of 16
65 · median 275
Started
2015
the only one that year
Phase 2
4 of 16
2 open now
Registered
2nd of 16
by date
Lead sponsor
12 of 16
AbbVie

Among the 16 studies testing risankizumab in Crohn Disease, this one is the 13th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 2, and was the 2nd registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 16 studies testing risankizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing risankizumab in Crohn Disease, or all of them as a file.
02

Study summary

The primary objective of the study was to investigate long-term safety of risankizumab (BI 655066/ABBV-066) in participants with moderately to severely active Crohn's disease who showed a clinical response or remission on previous treatment with risankizumab in Study NCT02031276 (BI trial 1311.6/ AbbVie M15-993) and were now receiving long-term treatment. Additional objectives of this study were to further investigate long-term efficacy, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of risankizumab.

Read the detailed description

This was a single group, open-label long-term extension study that assessed the long-term safety, efficacy, and pharmacokinetics of risankizumab in participants with moderately to severely active Crohn's disease. This study was terminated early by AbbVie to enable participants who completed the study to rollover into Study NCT03105102 (AbbVie M16-000 Sub-Study 3 [Phase 3 OLE study]) for further OLE treatment within the Phase 3 program, which allows for risankizumab dose escalation if needed.

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • ABBV-066
  • BI 655066
  • Risankizumab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Crohn's disease, who had successfully completed the preceding trial NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Successful treatment is defined as:

    1. Completion of period 2 in 1311.6 with a clinical response (drop in Crohn's Disease Activity Index (CDAI) from baseline by ≥100) but no remission (CDAI \< 150) at Visit E1; or
    2. Completion of period 3 in 1311.6 with a clinical response (drop in CDAI from baseline by ≥100) and/or remission (CDAI \< 150) at Visit E5; or
    3. Completion of period 2 or 3 in 1311.6 per protocol with a clinical response or remission before initiation of 1311.20 can roll-over either directly if that response/remission is maintained or through an open-label i.v. re-induction phase if they have lost their previous response/remission.
  • Female participants:

    1. Women of (not surgically sterilized and between menarche and 1 year ), that, if sexually active agree to use one of the appropriate medically accepted methods of in addition to the consistent and correct use of a condom from date of screening until 20 weeks after last administration of study medication. Medically accepted methods of contraception are: ethinyl estradiol containing contraceptives, diaphragm with spermicide substance, and intrauterine device, or
    2. Surgically sterilized female participants with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy, or
    3. Postmenopausal women with postmenopausal is defined as permanent cessation >/=1 year of previously occurring menses, and
    4. Negative serum ß-Human Chorionic Gonadotrophin test at screening and urine pregnancy test prior to randomization.
  • Male participants:

    1. Who are documented to be sterile, or
    2. Who consistently and correctly use effective method of contraception (i.e. condoms) during the study and 20 weeks after last administration of study medication.
  • Be able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Participants who were not compliant with key study procedures (colonoscopy, treatment compliance, endpoint assessment, measures) in preceding trial 1311.6
  • Participants who could not tolerate risankizumab (BI 655066/ ABBV-066) treatment for tolerability or safety reasons in the preceding trial
  • Are pregnant, nursing, or planning pregnancy while enrolled in the study, or within 20 weeks after receiving the last dose of study medication.
  • Participants must agree not to receive a live virus or bacterial or Bacille Calmette-Guérin vaccination during the study or up to 12 months after the last administration of study drug.
  • Participants who have developed , or suspicion of active malignant disease during the preceding trial
  • Are intending to participate in any other study using an agent or procedure during participation in this study.
  • Cannot adhere to the concomitant medication requirements
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Risankizumab

    Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.

    Drug: Risankizumab 600 mg IV · Drug: Risankizumab 180 mg SC

Interventions

  • Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained

    Also known as: BI 655066, ABBV-066

  • Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.

    Also known as: BI 655066, ABBV-066

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    A treatment emergent adverse event was defined as an event that occurred or worsened on or after the first dose of study drug through 140 days after the last dose in the current study for participants not rolling over into M16-000 Sub-study 3 or until the first dose of study drug in NCT03105102. All treatment-emergent serious and nonserious adverse events were collected, whether elicited or spontaneously reported by the participant.

    Time frame: From the time of study drug administration until 140 days after the last dose of study drug in the current study or until the first dose of study drug in NCT03105102 (AbbVie M16-000 Sub-study 3), up to 4 years for participants who rolled-over

Secondary outcomes

  1. Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Remission by Visit

    The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score \< 150.

    Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184

  2. Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Response by Visit

    The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical response is defined as CDAI score \< 150 or a reduction from baseline of at least 100 points. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).

    Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184

  3. Percentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Remission by Visit

    The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Remission is defined as PRO-2 score \< 75.

    Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184

  4. Percentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Response by Visit

    The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. PRO-2 response is defined as a decrease from baseline of 50 points or more. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).

    Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184

  5. Percentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Remission by Visit

    CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Remission is defined as a score of 4 or less, by visit (or for participants with initial isolated ileitis a score of 2 or less).

    Time frame: Weeks 0, 48, 104, 152, and 200

  6. Percentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Response by Visit

    CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Response is defined as a score of 7 or less (or for participants with initial isolated ileitis \> 50% reduction from baseline). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).

    Time frame: Weeks 0, 48, 104, 152, and 200

  7. Percentage of Participants With Mucosal Healing by Visit

    Mucosal healing is defined as Crohn's Disease Endoscopy Index of Severity (CDEIS) ulcerations sub-score (deep ulceration, superficial ulceration, ulcerated stenosis) of 0 as evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The overall CDEIS score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity.

    Time frame: Weeks 0, 48, 104, 152, and 200

  8. Percentage of Participants Achieving Deep Remission by Visit

    Deep remission is defined as clinical remission (CDAI \< 150) and CDEIS remission (CDEIS score of 4 or less, by visit or for participants with initial isolated ileitis a score of 2 or less).

    Time frame: Weeks 0, 48, 104, 152, and 200

  9. Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission by Visit

    The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ remission is defined as IBDQ total score \> 170 points.

    Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192

  10. Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Response by Visit

    The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ response is defined as increase in IBDQ total score \>16 points from baseline. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).

    Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192

  11. Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) by Visit

    The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.

    Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184

  12. Mean Change From Baseline in Patient Reported Outcome 2 (PRO-2) Scores by Visit

    The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.

    Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184

  13. Mean Change From Baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS) by Visit

    CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.

    Time frame: Weeks 0, 48, 104, 152, and 200

  14. Mean Change From Baseline in Simple Endoscopic Score (SES-CD) by Visit

    SES-CD is calculated based the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.

    Time frame: Weeks 0, 48, 104, 152, and 200

  15. Mean Change From Baseline in Stool Frequency (SF) By Visit

    Participants were asked to record the frequency of liquid stools on a daily basis. The number of liquid stools in the prior 7 days was summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.

    Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184

  16. Mean Change From Baseline in Abdominal Pain (AP) Score By Visit

    Participants were asked to rate and record daily abdominal pain on a scale of 0 to 3 \[none (0), mild (1), moderate (2) and severe (3)\]. The ratings in the prior 7 days were summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.

    Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184

  17. Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score by Visit

    The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

    Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192

  18. Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain Score by Visit

    The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

    Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192

  19. Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic System Domain Score by Visit

    The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

    Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192

  20. Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Function Domain Score by Visit

    The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

    Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192

  21. Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Function Domain Score by Visit

    The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

    Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192

  22. Mean Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) by Visit

    Concentration of serum high-sensitivity C-reactive Protein (hs-CRP) was analyzed by a central laboratory. It is a general marker of inflammation that is sensitive to acute changes in inflammatory response, and higher levels indicate more inflammation. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.

    Time frame: Weeks 0, 8, 24, 40, 56, 72, 88, 104, 120, 128, 136, 152, 160, 176, and 184

  23. Mean Change From Baseline in Fecal Calprotectin (FCP) Profile by Visit

    Fecal calprotectin (FCP) is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Stool samples were analyzed by a central laboratory for fecal calprotectin levels. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.

    Time frame: Weeks 0, 24, 56, 88, 120, 152, and 184

07

Results

Posted Apr 24, 2020

Participant flow

Participant flow — Overall Study
MilestoneAll Risankizumab
Started65
Completed44
Not completed21
Withdrew: Adverse event7
Withdrew: Withdrew consent5
Withdrew: Loss of efficacy2
Withdrew: Pregnancy2
Withdrew: Subject decision2
Withdrew: Lack of response1
Withdrew: Reproductive plans1
Withdrew: Surgery planned-- not done1

Outcome measures

PrimaryNumber of Participants With Adverse Events

A treatment emergent adverse event was defined as an event that occurred or worsened on or after the first dose of study drug through 140 days after the last dose in the current study for participants not rolling over into M16-000 Sub-study 3 or until the first dose of study drug in NCT03105102. All treatment-emergent serious and nonserious adverse events were collected, whether elicited or spontaneously reported by the participant.

Time frame:
From the time of study drug administration until 140 days after the last dose of study drug in the current study or until the first dose of study drug in NCT03105102 (AbbVie M16-000 Sub-study 3), up to 4 years for participants who rolled-over
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsRisankizumab 600 mg IVRisankizumab 180 mg SCAll Risankizumab
Number of Participants With Adverse Events26060
SecondaryPercentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Remission by Visit

The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score \< 150.

Time frame:
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Remission by Visit
percentage of participantsRisankizumab 600 mg IVRisankizumab 180 mg SC
Week 025.0072.31
Week 425.00—
Week 825.0073.85
Week 16—71.88
Week 24—74.60
Week 32—78.69
Week 40—81.67
Week 48—79.31
Week 56—80.70
Week 64—87.27
Week 72—83.33
Week 80—79.25
Week 88—78.43
Week 96—84.62
Week 104—85.71
Week 112—87.50
Week 120—83.33
Week 128—86.96
Week 136—76.92
Week 144—78.38
Week 152—76.67
Week 160—78.26
Week 168—70.59
Week 176—60.00
Week 184—40.00
SecondaryPercentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Response by Visit

The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical response is defined as CDAI score \< 150 or a reduction from baseline of at least 100 points. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).

Time frame:
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Response by Visit
percentage of participantsRisankizumab 600 mg IVRisankizumab 180 mg SC
Week 050.0090.77
Week 475.00—
Week 8100.0098.46
Week 16—92.19
Week 24—95.24
Week 32—95.08
Week 40—96.67
Week 48—94.83
Week 56—92.98
Week 64—96.36
Week 72—94.44
Week 80—92.45
Week 88—92.16
Week 96—92.31
Week 104—93.88
Week 112—93.75
Week 120—93.75
Week 128—93.48
Week 136—92.31
Week 144—91.89
Week 152—93.33
Week 160—91.30
Week 168—82.35
Week 176—80.00
Week 184—80.00
SecondaryPercentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Remission by Visit

The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Remission is defined as PRO-2 score \< 75.

Time frame:
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Remission by Visit
percentage of participantsRisankizumab 600 mg IVRisankizumab 180 mg SC
Week 025.0073.85
Week 425.00—
Week 850.0080.00
Week 16—78.13
Week 24—77.78
Week 32—85.25
Week 40—83.33
Week 48—82.76
Week 56—87.72
Week 64—81.82
Week 72—81.48
Week 80—81.13
Week 88—82.35
Week 96—84.62
Week 104—85.71
Week 112—91.67
Week 120—85.42
Week 128—89.13
Week 136—87.50
Week 144—86.49
Week 152—86.67
Week 160—73.91
Week 168—77.78
Week 176—60.00
Week 184—40.00
SecondaryPercentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Response by Visit

The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. PRO-2 response is defined as a decrease from baseline of 50 points or more. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).

Time frame:
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Response by Visit
percentage of participantsRisankizumab 600 mg IVRisankizumab 180 mg SC
Week 050.0083.08
Week 450.00—
Week 850.0086.15
Week 16—90.63
Week 24—92.06
Week 32—86.89
Week 40—98.33
Week 48—93.10
Week 56—91.23
Week 64—90.91
Week 72—88.89
Week 80—88.68
Week 88—86.27
Week 96—88.46
Week 104—87.76
Week 112—87.50
Week 120—91.67
Week 128—91.30
Week 136—92.50
Week 144—89.19
Week 152—93.33
Week 160—86.96
Week 168—83.33
Week 176—100.00
Week 184—100.00
SecondaryPercentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Remission by Visit

CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Remission is defined as a score of 4 or less, by visit (or for participants with initial isolated ileitis a score of 2 or less).

Time frame:
Weeks 0, 48, 104, 152, and 200
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Remission by Visit
percentage of participantsRisankizumab 180 mg SC
Week 042.86
Week 4856.45
Week 10462.79
Week 15258.97
Week 20085.71
SecondaryPercentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Response by Visit

CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Response is defined as a score of 7 or less (or for participants with initial isolated ileitis \> 50% reduction from baseline). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).

Time frame:
Weeks 0, 48, 104, 152, and 200
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Response by Visit
percentage of participantsRisankizumab 180 mg SC
Week 058.73
Week 4872.58
Week 10481.40
Week 15282.05
Week 200100.00
SecondaryPercentage of Participants With Mucosal Healing by Visit

Mucosal healing is defined as Crohn's Disease Endoscopy Index of Severity (CDEIS) ulcerations sub-score (deep ulceration, superficial ulceration, ulcerated stenosis) of 0 as evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The overall CDEIS score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity.

Time frame:
Weeks 0, 48, 104, 152, and 200
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing by Visit
percentage of participantsRisankizumab 180 mg SC
Week 029.69
Week 4835.48
Week 10439.53
Week 15243.59
Week 20042.86
SecondaryPercentage of Participants Achieving Deep Remission by Visit

Deep remission is defined as clinical remission (CDAI \< 150) and CDEIS remission (CDEIS score of 4 or less, by visit or for participants with initial isolated ileitis a score of 2 or less).

Time frame:
Weeks 0, 48, 104, 152, and 200
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Deep Remission by Visit
percentage of participantsRisankizumab 180 mg SC
Week 034.92
Week 4847.54
Week 10453.49
Week 15242.86
Week 2000.00
SecondaryPercentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission by Visit

The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ remission is defined as IBDQ total score \> 170 points.

Time frame:
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission by Visit
percentage of participantsRisankizumab 180 mg SC
Week 062.50
Week 2458.46
Week 4870.00
Week 7269.23
Week 9672.55
Week 12070.83
Week 14465.00
Week 16869.57
Week 19266.67
SecondaryPercentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Response by Visit

The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ response is defined as increase in IBDQ total score \>16 points from baseline. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).

Time frame:
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Response by Visit
percentage of participantsRisankizumab 180 mg SC
Week 092.19
Week 2489.23
Week 4895.00
Week 7288.46
Week 9690.20
Week 12095.83
Week 14492.50
Week 16886.96
Week 192100.00
SecondaryMean Change From Baseline in Crohn's Disease Activity Index (CDAI) by Visit

The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.

Time frame:
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Reported as:
Mean · units on a scale
Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) by Visit
units on a scaleRisankizumab 600 mg IVRisankizumab 180 mg SC
Week 0-50.70 ± 84.565-198.47 ± 101.762
Week 4-92.68 ± 40.688—
Week 8-119.40 ± 32.967-206.75 ± 83.580
Week 16—-205.93 ± 92.837
Week 24—-194.34 ± 82.840
SecondaryMean Change From Baseline in Patient Reported Outcome 2 (PRO-2) Scores by Visit

The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.

Time frame:
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Reported as:
Mean · units on a scale
Mean Change From Baseline in Patient Reported Outcome 2 (PRO-2) Scores by Visit
units on a scaleRisankizumab 600 mg IVRisankizumab 180 mg SC
Week 0-27.75 ± 48.979-105.46 ± 58.807
Week 4-35.25 ± 27.011—
Week 8-53.75 ± 24.405-109.53 ± 49.419
Week 16—-108.32 ± 52.848
Week 24—-105.40 ± 50.167
Week 32—-109.41 ± 56.459
Week 40—-116.33 ± 43.511
Week 48—-111.29 ± 48.048
Week 56—-115.54 ± 51.279
Week 64—-113.02 ± 57.338
Week 72—-112.11 ± 56.819
Week 80—-106.42 ± 58.710
Week 88—-108.67 ± 51.214
Week 96—-109.81 ± 50.927
Week 104—-109.10 ± 49.562
Week 112—-109.75 ± 52.951
Week 120—-111.10 ± 47.360
Week 128—-113.02 ± 50.738
Week 136—-113.00 ± 51.575
Week 144—-115.35 ± 53.460
Week 152—-109.17 ± 56.659
Week 160—-96.70 ± 54.018
Week 168—-111.09 ± 55.287
Week 176—-103.06 ± 42.717
Week 184—-129.13 ± 70.484
SecondaryMean Change From Baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS) by Visit

CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.

Time frame:
Weeks 0, 48, 104, 152, and 200
Reported as:
Mean · units on a scale
Mean Change From Baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS) by Visit
units on a scaleRisankizumab 180 mg SC
Week 0-8.08 ± 5.973
Week 48-9.32 ± 6.014
Week 104-9.24 ± 6.035
Week 152-9.75 ± 7.254
Week 200-10.76 ± 5.209
SecondaryMean Change From Baseline in Simple Endoscopic Score (SES-CD) by Visit

SES-CD is calculated based the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.

Time frame:
Weeks 0, 48, 104, 152, and 200
Reported as:
Mean · units on a scale
Mean Change From Baseline in Simple Endoscopic Score (SES-CD) by Visit
units on a scaleRisankizumab 180 mg SC
Week 0-9.63 ± 8.001
Week 48-12.35 ± 7.753
Week 104-11.56 ± 8.060
Week 152-12.63 ± 9.139
Week 200-13.36 ± 7.521
SecondaryMean Change From Baseline in Stool Frequency (SF) By Visit

Participants were asked to record the frequency of liquid stools on a daily basis. The number of liquid stools in the prior 7 days was summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.

Time frame:
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Reported as:
Mean · number of liquid stools in prior 7 days
Mean Change From Baseline in Stool Frequency (SF) By Visit
number of liquid stools in prior 7 daysRisankizumab 600 mg IVRisankizumab 180 mg SC
Week 0-0.46 ± 2.319-4.13 ± 3.273
Week 4-0.46 ± 1.584—
Week 8-1.07 ± 1.421-4.22 ± 3.160
Week 16—-4.10 ± 3.223
Week 24—-4.19 ± 3.209
Week 32—-4.08 ± 3.536
Week 40—-4.58 ± 3.037
Week 48—-4.31 ± 3.278
Week 56—-4.48 ± 3.282
Week 64—-4.41 ± 3.514
Week 72—-4.25 ± 3.513
Week 80—-4.00 ± 3.469
Week 88—-4.04 ± 3.331
Week 96—-4.27 ± 3.037
Week 104—-4.00 ± 2.943
Week 112—-3.91 ± 2.951
Week 120—-3.99 ± 2.840
Week 128—-4.05 ± 3.060
Week 136—-3.95 ± 3.137
Week 144—-4.13 ± 3.308
Week 152—-4.00 ± 3.150
Week 160—-3.71 ± 3.044
Week 168—-4.08 ± 3.353
Week 176—-3.61 ± 2.583
Week 184—-4.50 ± 3.881
SecondaryMean Change From Baseline in Abdominal Pain (AP) Score By Visit

Participants were asked to rate and record daily abdominal pain on a scale of 0 to 3 \[none (0), mild (1), moderate (2) and severe (3)\]. The ratings in the prior 7 days were summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.

Time frame:
Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Reported as:
Mean · units on a scale
Mean Change From Baseline in Abdominal Pain (AP) Score By Visit
units on a scaleRisankizumab 600 mg IVRisankizumab 180 mg SC
Week 0-0.61 ± 1.006-1.36 ± 0.885
Week 4-0.82 ± 0.768—
Week 8-1.11 ± 0.357-1.44 ± 0.746
Week 16—-1.45 ± 0.773
Week 24—-1.33 ± 0.804
Week 32—-1.49 ± 0.760
Week 40—-1.49 ± 0.766
Week 48—-1.46 ± 0.720
Week 56—-1.51 ± 0.815
Week 64—-1.47 ± 0.825
Week 72—-1.50 ± 0.839
Week 80—-1.44 ± 0.816
Week 88—-1.49 ± 0.787
Week 96—-1.43 ± 0.881
Week 104—-1.52 ± 0.861
Week 112—-1.57 ± 0.890
Week 120—-1.58 ± 0.735
Week 128—-1.61 ± 0.776
Week 136—-1.65 ± 0.792
Week 144—-1.64 ± 0.836
Week 152—-1.52 ± 0.833
Week 160—-1.28 ± 0.788
Week 168—-1.54 ± 0.657
Week 176—-1.50 ± 0.670
Week 184—-1.89 ± 0.921
SecondaryMean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score by Visit

The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

Time frame:
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Mean · units on a scale
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score by Visit
units on a scaleRisankizumab 180 mg SC
Week 062.48 ± 38.791
Week 2458.72 ± 35.626
Week 4864.03 ± 33.039
Week 7264.14 ± 42.229
Week 9662.38 ± 39.220
Week 12067.28 ± 34.390
Week 14461.34 ± 34.894
Week 16856.36 ± 33.035
Week 19271.17 ± 41.911
SecondaryMean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain Score by Visit

The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

Time frame:
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Mean · units on a scale
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain Score by Visit
units on a scaleRisankizumab 180 mg SC
Week 020.44 ± 11.680
Week 2418.26 ± 11.587
Week 4820.29 ± 10.861
Week 7220.64 ± 12.547
Week 9619.12 ± 13.064
Week 12022.25 ± 10.473
Week 14420.46 ± 10.639
Week 16818.44 ± 10.658
Week 19222.67 ± 14.962
SecondaryMean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic System Domain Score by Visit

The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

Time frame:
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Mean · units on a scale
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic System Domain Score by Visit
units on a scaleRisankizumab 180 mg SC
Week 09.9 ± 6.66
Week 249.1 ± 6.44
Week 489.6 ± 6.08
Week 7210.1 ± 7.36
Week 9610.3 ± 5.80
Week 1209.8 ± 6.16
Week 1448.9 ± 6.02
Week 1688.2 ± 5.10
Week 19211.8 ± 4.62
SecondaryMean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Function Domain Score by Visit

The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

Time frame:
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Mean · units on a scale
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Function Domain Score by Visit
units on a scaleRisankizumab 180 mg SC
Week 011.04 ± 8.230
Week 2410.57 ± 7.652
Week 4811.64 ± 7.487
Week 7211.20 ± 8.731
Week 9610.59 ± 8.556
Week 12011.92 ± 7.347
Week 14410.93 ± 8.309
Week 16810.87 ± 9.503
Week 19211.67 ± 9.266
SecondaryMean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Function Domain Score by Visit

The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.

Time frame:
Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Mean · units on a scale
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Function Domain Score by Visit
units on a scaleRisankizumab 180 mg SC
Week 021.09 ± 16.820
Week 2420.79 ± 15.632
Week 4822.55 ± 14.965
Week 7222.23 ± 17.912
Week 9622.41 ± 17.075
Week 12023.35 ± 15.391
Week 14421.03 ± 15.044
Week 16818.87 ± 14.552
Week 19225.00 ± 21.373
SecondaryMean Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) by Visit

Concentration of serum high-sensitivity C-reactive Protein (hs-CRP) was analyzed by a central laboratory. It is a general marker of inflammation that is sensitive to acute changes in inflammatory response, and higher levels indicate more inflammation. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.

Time frame:
Weeks 0, 8, 24, 40, 56, 72, 88, 104, 120, 128, 136, 152, 160, 176, and 184
Reported as:
Mean · mg/L
Mean Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) by Visit
mg/LRisankizumab 180 mg SC
Week 0-14.64 ± 22.842
Week 8-15.84 ± 22.548
Week 24-12.76 ± 24.457
Week 40-14.32 ± 24.080
Week 56-16.11 ± 24.194
Week 72-14.40 ± 21.878
Week 88-17.07 ± 23.312
Week 104-14.44 ± 20.057
Week 120-13.81 ± 22.667
Week 128-14.87 ± 20.133
Week 136-15.78 ± 20.864
Week 152-17.03 ± 20.998
Week 160-18.43 ± 22.147
Week 176-20.49 ± 25.062
Week 184-25.01 ± 32.459
SecondaryMean Change From Baseline in Fecal Calprotectin (FCP) Profile by Visit

Fecal calprotectin (FCP) is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Stool samples were analyzed by a central laboratory for fecal calprotectin levels. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.

Time frame:
Weeks 0, 24, 56, 88, 120, 152, and 184
Reported as:
Mean · μg/g
Mean Change From Baseline in Fecal Calprotectin (FCP) Profile by Visit
μg/gRisankizumab 180 mg SC
Week 0-1983.9 ± 3402.12
Week 24-2166.4 ± 4035.66
Week 56-2277.8 ± 4104.19
Week 88-2485.9 ± 4157.37
Week 120-2031.9 ± 5187.92
Week 152-2631.5 ± 4589.62
Week 184-4436.1 ± 7455.55

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 140 days after the last dose of study drug in the current study or until the first dose of study drug in NCT03105102 (AbbVie M16-000 Sub-study 3), up to 4 years for participants who rolled-over.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risankizumab 600 mg IV0/4 (0%)0/4 (0%)2/4 (50%)
Risankizumab 180 mg SC0/65 (0%)23/65 (35.4%)52/65 (80%)
All Risankizumab0/65 (0%)23/65 (35.4%)52/65 (80%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventRisankizumab 600 mg IVRisankizumab 180 mg SCAll Risankizumab
Crohn's diseaseGastrointestinal disorders0/42/652/65
Intestinal stenosisGastrointestinal disorders0/42/652/65
Gastroenteritis viralInfections and infestations0/42/652/65
PeritonitisInfections and infestations0/42/652/65
Post procedural complicationInjury, poisoning and procedural complications0/42/652/65
Iron deficiency anaemiaBlood and lymphatic system disorders0/41/651/65
TachycardiaCardiac disorders0/41/651/65
Adrenal insufficiencyEndocrine disorders0/41/651/65
Abdominal pain upperGastrointestinal disorders0/41/651/65
Dumping syndromeGastrointestinal disorders0/41/651/65
Most frequent other events
Showing 10 of 39
Most frequent other events
EventRisankizumab 600 mg IVRisankizumab 180 mg SCAll Risankizumab
NasopharyngitisInfections and infestations1/420/6520/65
Ear painEar and labyrinth disorders1/40/651/65
Abdominal pain upperGastrointestinal disorders1/44/655/65
HaematocheziaGastrointestinal disorders1/42/652/65
OdynophagiaGastrointestinal disorders1/40/651/65
VomitingGastrointestinal disorders1/44/655/65
Upper respiratory tract infectionInfections and infestations1/47/657/65
Weight increasedInvestigations1/42/652/65
Vitamin B12 deficiencyMetabolism and nutrition disorders1/42/653/65
GastroenteritisInfections and infestations0/415/6515/65

Baseline characteristics

Intent-to-Treat population: all participants who received at least one dose of risankizumab in the current study

Age, Continuous
Age, Continuous(years)All Risankizumab
Mean37.1 ± 12.97
Sex: Female, Male
Sex: Female, Male(Participants)All Risankizumab
Female36
Male29
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Risankizumab
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American0
White55
More than one race0
Unknown or Not Reported0
Baseline Corticosteroid Use
Baseline Corticosteroid Use(Participants)All Risankizumab
Yes21
No44
Missing0
Tumor Necrosis Factor (TNF) Antagonist Exposure
Tumor Necrosis Factor (TNF) Antagonist Exposure(Participants)All Risankizumab
Anti-TNF Experienced60
Anti-TNF Naive5
Missing0
Crohn's Disease Activity Index (CDAI)
Crohn's Disease Activity Index (CDAI)(units on a scale)All Risankizumab
Mean304.771 ± 77.9832
High-sensitivity C-Reactive Protein (hs-CRP)
High-sensitivity C-Reactive Protein (hs-CRP)(mg/L)All Risankizumab
Mean20.315 ± 23.1676
08

Study locations

28 sites
  • MGG Group, Inc.Chevy Chase Clinical Research /ID# 155068
    Chevy Chase, Maryland 20815, United States
  • Clin Res Inst of Michigan, LLC /ID# 155066
    Chesterfield, Michigan 48047, United States
  • Cliniques Universitaires Saint Luc /ID# 154985
    Woluwe-Saint-Lambert, Bruxelles-Capitale 1200, Belgium
  • CHU de Liege /ID# 154988
    Liège, Liege 4000, Belgium
  • Imelda Ziekenhuis /ID# 154984
    Bonheiden, 2820, Belgium
  • ULB Erasme /ID# 154987
    Brussels, 1070, Belgium
  • AZ Groeninge /ID# 154989
    Kortrijk, 8500, Belgium
  • UZ Leuven /ID# 154986
    Leuven, 3000, Belgium
  • AZ-Delta /ID# 154983
    Roeselare, 8800, Belgium
  • McMaster University Med Cent /ID# 155019
    Hamilton, Ontario L8S 4K1, Canada
  • Universitaetsklinikum Erlangen /ID# 155039
    Erlangen, Bayern 91054, Germany
  • Med Hochschule Hanover /ID# 155041
    Hannover, 30625, Germany
  • Yeungnam University Med Ctr /ID# 155056
    Daegu, Daegu Gwang Yeogsi 42415, Korea, Republic of
  • Kangbuk Samsung Hospital /ID# 155054
    Jongno-Gu, Seoul Teugbyeolsi 03181, Korea, Republic of
  • Severance Hospital /ID# 155055
    Seoul, Seoul Teugbyeolsi 03722, Korea, Republic of
  • Asan Medical Center /ID# 155053
    Seoul, 05505, Korea, Republic of
  • Academisch Medisch Centrum /ID# 155058
    Amsterdam, Noord-Holland 1105 AZ, Netherlands
  • Maastricht Universitair Medisch Centrum /ID# 155059
    Maastricht, 6229 HX, Netherlands
  • NZOZ Vivamed /ID# 155061
    Warsaw, 03-580, Poland
  • Lexmedica /Id# 155062
    Wroclaw, 53-114, Poland
  • Hospital Duran i Reynals /ID# 155063
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Clinic de Barcelona /ID# 155064
    Barcelona, 08036, Spain
  • Hospital Univ de la Princesa /ID# 155065
    Madrid, 28006, Spain
  • Guy's and St Thomas' NHS Found /ID# 155046
    London, London, City Of SE1 9RT, United Kingdom
  • Addenbrookes Hospital /ID# 155047
    Cambridge, CB2 0SP, United Kingdom
  • St. James University Hospital /ID# 155050
    Leeds, LS9 7TF, United Kingdom
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 155049
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
  • John Radcliffe Hospital /ID# 155048
    Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Ferrante M, Feagan BG, Panes J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. J Crohns Colitis. 2021 Dec 18;15(12):2001-2010. doi: 10.1093/ecco-jcc/jjab093. PubMed 34077509 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jun 2019, 45 months.

Results were first posted in Apr 2020, 10 months after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 45 months is above that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2015
First posted
Jul 31, 2015
StartActual
Sep 16, 2015
Primary completionActual
Jun 19, 2019
CompletionActual
Jun 19, 2019
Results first posted
Apr 24, 2020
Last update
Apr 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02513459
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 31, 2015
Start date
Sep 16, 2015
Primary completion
Jun 19, 2019
Completion
Jun 19, 2019
Results posted
Apr 24, 2020
Last update
Apr 24, 2020

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion